Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia
Background: HER2-targeting therapies may increase the risk of decreased left ventricular ejection fraction (LVEF), potentially leading to heart failure. The growing number of breast cancer survivors due to HER2-targeted treatments necessitates long-term cardiotoxicity management. Method: This retros...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/11795549241297881 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124256616120320 |
|---|---|
| author | Alaa Shahbar Abdullah A Alhifany Yasser M Alatawi Mohammed Alnuhait Abdullah Alshammari Majed Alshamrani Abdulhalim Kinsara Atif AlQubbany Mahasen Alharbi Abdelmajid Alnatsheh Meteb Alfoheidi |
| author_facet | Alaa Shahbar Abdullah A Alhifany Yasser M Alatawi Mohammed Alnuhait Abdullah Alshammari Majed Alshamrani Abdulhalim Kinsara Atif AlQubbany Mahasen Alharbi Abdelmajid Alnatsheh Meteb Alfoheidi |
| author_sort | Alaa Shahbar |
| collection | DOAJ |
| description | Background: HER2-targeting therapies may increase the risk of decreased left ventricular ejection fraction (LVEF), potentially leading to heart failure. The growing number of breast cancer survivors due to HER2-targeted treatments necessitates long-term cardiotoxicity management. Method: This retrospective study included HER2-positive breast cancer patients aged 18 or older who received at least 1 dose of HER2-targeting treatment between 2016 and 2020. The primary endpoint was the incidence of cardiotoxicity, defined as LVEF <50% with a 10% decline, LVEF drop by >15%, or onset of symptomatic heart failure. Secondary endpoints included the proportion of patients with baseline LVEF 50% to 55% developing cardiotoxicity, those discontinuing HER2 therapy due to heart failure, those treated with heart failure medications, and those continuing HER2 therapy while on heart failure medications. Another secondary outcome was the development of a hospital protocol for monitoring cardiotoxicity in these patients. Results: A total of 212 patients were included, with a median age of 56.5 years (interquartile range: 43-58 years). Twenty-two patients (10.37%) experienced cardiotoxicity from HER2-targeted treatment. Thirteen patients (6.13%) had asymptomatic heart failure with LVEF decrease of more than 10% to less than 50%. Five patients (2.35%) with LVEF less than 40% had asymptomatic heart failure, while 4 patients (1.88%) had symptomatic heart failure regardless of LVEF decline. HER2-targeted treatment was temporarily discontinued in 3 (13.63%) patients and permanently in 4 (18.18%) patients due to cardiotoxicity. The remaining 15 patients resumed treatment without interruption. Only 13 out of 22 patients were referred to cardiologists and prescribed heart failure medications. Conclusion: Close monitoring of LVEF in patients receiving HER2-targeting therapy can help health care providers initiate anti-heart failure medications to prevent LVEF deterioration and maintain HER2-targeting therapy. |
| format | Article |
| id | doaj-art-7bf42f8ecd4346dd9706b0c998933a33 |
| institution | OA Journals |
| issn | 1179-5549 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj-art-7bf42f8ecd4346dd9706b0c998933a332025-08-20T02:34:20ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492024-11-011810.1177/11795549241297881Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi ArabiaAlaa Shahbar0Abdullah A Alhifany1Yasser M Alatawi2Mohammed Alnuhait3Abdullah Alshammari4Majed Alshamrani5Abdulhalim Kinsara6Atif AlQubbany7Mahasen Alharbi8Abdelmajid Alnatsheh9Meteb Alfoheidi10Pharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaPharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi ArabiaPharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaPharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaPharmaceutical Care Department, King Abdul-Aziz Medical City, Jeddah, Saudi ArabiaCardiovascular Diseases Department, King Abdullah International Medical Research Center, Jeddah, Saudi ArabiaCardiovascular Diseases Department, King Abdullah International Medical Research Center, Jeddah, Saudi ArabiaPharmaceutical Care Department, King Abdul-Aziz Medical City, Jeddah, Saudi ArabiaPharmaceutical Care Department, King Abdul-Aziz Medical City, Jeddah, Saudi ArabiaDepartment of Oncology, Ministry of National Guard Health Affairs, Jeddah, Saudi ArabiaBackground: HER2-targeting therapies may increase the risk of decreased left ventricular ejection fraction (LVEF), potentially leading to heart failure. The growing number of breast cancer survivors due to HER2-targeted treatments necessitates long-term cardiotoxicity management. Method: This retrospective study included HER2-positive breast cancer patients aged 18 or older who received at least 1 dose of HER2-targeting treatment between 2016 and 2020. The primary endpoint was the incidence of cardiotoxicity, defined as LVEF <50% with a 10% decline, LVEF drop by >15%, or onset of symptomatic heart failure. Secondary endpoints included the proportion of patients with baseline LVEF 50% to 55% developing cardiotoxicity, those discontinuing HER2 therapy due to heart failure, those treated with heart failure medications, and those continuing HER2 therapy while on heart failure medications. Another secondary outcome was the development of a hospital protocol for monitoring cardiotoxicity in these patients. Results: A total of 212 patients were included, with a median age of 56.5 years (interquartile range: 43-58 years). Twenty-two patients (10.37%) experienced cardiotoxicity from HER2-targeted treatment. Thirteen patients (6.13%) had asymptomatic heart failure with LVEF decrease of more than 10% to less than 50%. Five patients (2.35%) with LVEF less than 40% had asymptomatic heart failure, while 4 patients (1.88%) had symptomatic heart failure regardless of LVEF decline. HER2-targeted treatment was temporarily discontinued in 3 (13.63%) patients and permanently in 4 (18.18%) patients due to cardiotoxicity. The remaining 15 patients resumed treatment without interruption. Only 13 out of 22 patients were referred to cardiologists and prescribed heart failure medications. Conclusion: Close monitoring of LVEF in patients receiving HER2-targeting therapy can help health care providers initiate anti-heart failure medications to prevent LVEF deterioration and maintain HER2-targeting therapy.https://doi.org/10.1177/11795549241297881 |
| spellingShingle | Alaa Shahbar Abdullah A Alhifany Yasser M Alatawi Mohammed Alnuhait Abdullah Alshammari Majed Alshamrani Abdulhalim Kinsara Atif AlQubbany Mahasen Alharbi Abdelmajid Alnatsheh Meteb Alfoheidi Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia Clinical Medicine Insights: Oncology |
| title | Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia |
| title_full | Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia |
| title_fullStr | Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia |
| title_full_unstemmed | Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia |
| title_short | Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia |
| title_sort | assessment of cardiotoxicity incidence in patients receiving her 2 targeted therapies for breast cancer in saudi arabia |
| url | https://doi.org/10.1177/11795549241297881 |
| work_keys_str_mv | AT alaashahbar assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT abdullahaalhifany assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT yassermalatawi assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT mohammedalnuhait assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT abdullahalshammari assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT majedalshamrani assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT abdulhalimkinsara assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT atifalqubbany assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT mahasenalharbi assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT abdelmajidalnatsheh assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia AT metebalfoheidi assessmentofcardiotoxicityincidenceinpatientsreceivingher2targetedtherapiesforbreastcancerinsaudiarabia |